WAVE Life Sciences (WVE) to Post Earnings on Thursday

WAVE Life Sciences (NASDAQ:WVE) is expected to be announcing its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect WAVE Life Sciences to post earnings of ($0.31) per share and revenue of $7.45 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:30 AM ET.

WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Wednesday, April 29th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.21. WAVE Life Sciences had a negative return on equity of 56.76% and a negative net margin of 255.70%.The company had revenue of $38.25 million for the quarter, compared to analysts’ expectations of $8.45 million. On average, analysts expect WAVE Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

WAVE Life Sciences Price Performance

Shares of NASDAQ WVE opened at $5.89 on Wednesday. WAVE Life Sciences has a one year low of $5.02 and a one year high of $21.73. The firm’s 50 day simple moving average is $6.01 and its two-hundred day simple moving average is $9.12. The stock has a market capitalization of $1.13 billion, a P/E ratio of -5.56 and a beta of -1.29.

Hedge Funds Weigh In On WAVE Life Sciences

Several hedge funds and other institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of WAVE Life Sciences by 9.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,349 shares of the company’s stock valued at $463,000 after buying an additional 4,957 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of WAVE Life Sciences by 3.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 557,644 shares of the company’s stock worth $4,506,000 after purchasing an additional 20,624 shares in the last quarter. Rhumbline Advisers boosted its position in shares of WAVE Life Sciences by 22.5% in the 2nd quarter. Rhumbline Advisers now owns 162,599 shares of the company’s stock worth $1,057,000 after purchasing an additional 29,899 shares in the last quarter. Prudential Financial Inc. purchased a new stake in shares of WAVE Life Sciences in the 2nd quarter worth approximately $80,000. Finally, Norges Bank purchased a new stake in shares of WAVE Life Sciences in the 2nd quarter worth approximately $650,000. 89.73% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

WVE has been the subject of a number of recent research reports. Zacks Research upgraded shares of WAVE Life Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. Wall Street Zen raised shares of WAVE Life Sciences from a “strong sell” rating to a “hold” rating in a report on Saturday, May 2nd. Truist Financial began coverage on shares of WAVE Life Sciences in a research report on Wednesday, April 29th. They issued a “buy” rating and a $15.00 target price on the stock. HC Wainwright reiterated a “buy” rating on shares of WAVE Life Sciences in a research report on Thursday, June 11th. Finally, Citigroup lowered their price target on shares of WAVE Life Sciences from $30.00 to $24.00 and set a “buy” rating for the company in a research note on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $26.41.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.